Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Develop Assay as CDx for Ferring's Infertility Treatment

NEW YORK (GenomeWeb) – Roche will develop an existing assay as a companion diagnostic for Ferring Pharmaceuticals' potential infertility treatment under a deal announced today.

Roche will qualify, validate, document, and seek regulatory approval for its test, the Elecsys AMH assay, for use in combination with Ferring's human cell line-derived recombinant follicle-stimulating hormone, a gonadotrophin in phase III development. The Elecsys AMH assay evaluates anti-Müllerian hormone levels, a measure of a woman's ovarian reserve and her response to infertility treatment with gonadotrophin, Roche and Ferring said.

The assay runs on Roche's cobas electrochemiluminescence immunoassay platform and takes about 18 minutes to produce results, compared to several hours with manual AMH testing, they added. The test would allow physicians to personalize dosing of Ferring's treatment and could improve the predictability of infertility treatment, lowering the burden of treatment for women using assisted reproductive technology for conception.

Financial and other terms of the deal were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.